Search Results - "Tilki, D."

Refine Results
  1. 1

    Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model by Nguyen, H G, Yang, J C, Kung, H-J, Shi, X-B, Tilki, D, Lara, P N, DeVere White, R W, Gao, A C, Evans, C P

    Published in Oncogene (04-09-2014)
    “…Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic…”
    Get full text
    Journal Article
  2. 2

    Intraoperative technologies to assess margin status during radical prostatectomy - a narrative review by Windisch, O, Diana, M, Tilki, D, Marra, G, Martini, A, Valerio, M

    Published in Prostate cancer and prostatic diseases (18-07-2024)
    “…Positive surgical margin (PSM) is a frequent concern for surgeons performing radical prostatectomy for prostate cancer (PCa). PSM are recognized as risk…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach? by Marra, Giancarlo, Ploussard, Guillaume, Futterer, Jurgen, Valerio, Massimo

    Published in World journal of urology (01-02-2019)
    “…Purpose To review the evidence addressing current controversies around prostate biopsy. Specific questions explored were (1) mpMRI targeted (TgBx) alone versus…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    The current role of precision surgery in oligometastatic prostate cancer by von Deimling, M., Rajwa, P., Tilki, D., Heidenreich, A., Pallauf, M., Bianchi, A., Yanagisawa, T., Kawada, T., Karakiewicz, P.I., Gontero, P., Pradere, B., Ploussard, G., Rink, M., Shariat, S.F.

    Published in ESMO open (01-12-2022)
    “…Oligometastatic prostate cancer (omPCa) is a novel intermediate disease state characterized by a limited volume of metastatic cells and specific locations…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent by Benezra, M, Phillips, E, Tilki, D, Ding, B-S, Butler, J, Dobrenkov, K, Siim, B, Chaplin, D, Rafii, S, Rabbany, S, Bradbury, M S

    Published in Leukemia (01-08-2012)
    “…Advances in the treatment of acute leukemia have resulted in significantly improved remission rates, although disease relapse poses a significant risk. By…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20